Safety and efficacy of ferric carboxy maltose in pregnant women- a pilot study


  • Vijaya Harsoor Department of Obstetrics and Gynecology, VIMS, Ballari, Karnataka, India
  • Shaila Chikkagowdra Department of Obstetrics and Gynecology, VIMS, Ballari, Karnataka, India
  • Aniruddha R. H. Department of Obstetrics and Gynecology, AIMS and RC, Devanahalli, Bengaluru, Karnataka, India
  • Vanaja D. Department of Obstetrics and Gynecology, VIMS, Ballari, Karnataka, India



Iron deficiency, Ferric carboxy maltose, Parenteral iron therapy, Peripartum anemia


Background: Iron deficiency is a common nutritional deficiency amongst women of childbearing age. It is associated with significant maternal, fetal and infant morbidity. Current options for treatment include oral iron, parenteral iron and red blood cell transfusions. Ferric carboxy maltose is a newer i.v. iron formulation which can be used at high doses with rapid administration. This study was undertaken to assess the safety and efficacy in pregnant women.

Methods: Prospective observational study was conducted in VIMS Ballari. 50 pregnant women between 28-36 weeks of gestation having moderate anemia with confirmed iron deficiency were administered with 1000 mg of ferric carboxy maltose (FCM). These women were followed after 2 weeks, 4 weeks and till delivery. Safety and efficacy were assessed.

Results: There was significant improvement in both hemoglobin and serum ferritin levels (p<0.01). None of them had significant reactions.

Conclusions: Ferric carboxy maltose is well tolerated. Ability to transfuse in single high dose makes it a preferred drug for faster and higher replenishment of iron stores and correction of hemoglobin levels during pregnancy especially in third trimester.

Author Biography

Shaila Chikkagowdra, Department of Obstetrics and Gynecology, VIMS, Ballari, Karnataka, India

associate professor

dept of obg



Mishra V, Gandhi K, Roy P, Hokabaj S, Shah KN. Role of intravenous ferric carboxy-maltose in pregnant women with iron deficiency anaemia. J Nepal Health Res Counc. 2017;15(2):96-99.

Neiser S, Wilhelm M, Schwarz K, Funk F, Geisser P, Burckhardt S. Assessment of dextran antigenicity of intravenous iron products by an immunodiffusion assay. Portuguese J Nephrol Hypertens. 2011;25(3):219-24.

Geisser P. The pharmacology and safety profile of ferric carboxymaltose (Ferinject): structure/reactivity relationships of iron preparations. Portuguese J Nephrol Hypertens. 2009;23(1):11-6.

Rai RK, Fawzi WW, Barik A, Chowdhury A. The burden of iron-deficiency anaemia among women in India: how have iron and folic acid interventions fared? WHO South-East Asia J Public Health. 2018;7(1):18-23.

Lone FW, Qureshi RN, Emmanuel F. Maternal anaemia and its impact on perinatal outcome in a tertiary care hospital in Pakistan. East Mediterr Health J. 2004;10(6):801-7.

Beard J. Recent evidence from human and animal studies regarding iron status and infant development. J Nutr. 2007;137(2):524S-30S.

Perez EM, Hendricks MK, Beard JL, Murray-Kolb LE, Berg A, Tomlinson M, et al. Mother-infant interactions and infant development are altered by maternal iron deficiency anemia. J Nutr. 2005;135(4):850-5.

Gautam CS, Saha L, Sekhri K, Saha PK. Iron deficiency in pregnancy and the rationality of iron supplements prescribed during pregnancy. Medscape J Med. 2008;10(12):283.

Bodnar LM, Cogswell ME, McDonald T. Have we forgotten the significance of postpartum iron deficiency? Am J Obstet Gynecol. 2005;193(1):36-44.

Ehrenthal DB, Chichester ML, Cole OS, Jiang X. Maternal risk factors for peripartum transfusion. J Womens Health. 2012;21(7):792-7.

Milman N. Postpartum anemia II: prevention and treatment. Ann Hematol. 2012;91(2):143-54.

Khalafallah A, Dennis A, Bates J, Bates G, Robertson IK, Smith L, et al. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med. 2010;268(3):286-95.

Froessler B, Cocchiaro C, Saadat-Gilani K, Hodyl N, Dekker G. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial. J Matern Fet Neonat Med. 2013;26(7):654-9.

Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT®) randomized controlled trial. Am J Gastroenterol. 2008;103(5):1182-92.

Steinmetz T, Tschechne B, Harlin O. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013;24(2):475-82.

Evstatiev R, Marteau P, Iqbal T. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3)e2:846-53.

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48.

Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Blood Management: large‐dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49(12):2719-28.

Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dialysis Transplant. 2011;26(5)1599-607.

Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dialysis Transplant. 2010;25(8): 2722-30.

Bailie GR, Mason NA, Valaoras TG. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hemodial Int. 2010;14(1):47-54.

Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199(4):435-e1.

Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110(2 Part 1):267-78.

Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynecol Obstet. 2008;101(1):67-73.

Pfenniger A, Schuller C, Christoph P, Surbek D. Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia. J Perinat Med. 2012;40(4):397-402.

Christoph P, Schuller C, Studer H, Irion O, De Tejada BM, Surbek D. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose. J Perinat Med. 2012;40(5):469-74.

Myers B, Myers O, Moore J. Comparative efficacy and safety of intravenous ferric carboxymaltose (Ferinject) and iron (III) hydroxide dextran (Cosmofer) in pregnancy. Obstet Med. 2012;5(3):105-7.

Froessler B, Collingwood J, Hodyl NA, Dekker G. Intravenous ferric carboxymaltose for anaemia in pregnancy. BMC Pregnanc Childbirth. 2014;14(1):1-5.

Froessler B, Dekker G, McAuliffe G. To the rescue: the role of intravenous iron in the management of severe anaemia in the peri-partum setting. Blood Transfus. 2015;13(1):150-2.

Qassim A, Mol BW, Grivell RM, Grzeskowiak LE. Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: a systematic review. ANZ J Obstet Gynaecol. 2018;58(1):22-39.

Mahey R, Kriplani A, Mogili KD, Bhatla N, Kachhawa G, Saxena R. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Int J Gynaecol Obstet. 2016;133(1):43-8.






Original Research Articles